Thermo Fisher Scientific Specialty Diagnostics — Operating Income (Loss) increased by 9.6% to $321.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 9.6%, from $293.00M to $321.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates improved operational efficiency and profitability, while a decrease signals margin pressure or rising costs.
The profit or loss generated by the Specialty Diagnostics segment after deducting all operating expenses, including cost...
The standard measure for comparing the operational health of business segments across the industry.
tmo_segment_specialty_diagnostics_operating_income_loss| Q2 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $245.00M | $353.00M | $243.00M | $281.00M | $281.00M | $281.00M | $281.00M | $293.00M | $321.00M |
| QoQ Change | — | +44.1% | -31.2% | +15.6% | +0.0% | +0.0% | +0.0% | +4.3% | +9.6% |
| YoY Change | — | — | -0.8% | -20.4% | +15.6% | — | — | +4.3% | +9.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.